Schroder Investment Management Group Genmab A/S Transaction History

Schroder Investment Management Group

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$26.43 - $32.77 $3.04 Million - $3.77 Million	115,085 Added 90.4%	242,385 $7.25 Million
Q4 2023 Feb 13, 2024	BUY	$27.94 - $35.44 $3.56 Million - $4.51 Million	127,300 New	127,300 $4.05 Million
Q4 2022 Feb 10, 2023	BUY	$33.8 - $47.06 $1.27 Million - $1.77 Million	37,579 New	37,579 $1.59 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $2.7 Million - $3.54 Million	-75,150 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$41.55 - $48.72 $50 Million - $58.6 Million	-1,202,475 Reduced 94.12%	75,150 $32.8 Million
Q2 2021 Aug 13, 2021	BUY	$32.88 - $44.57 $22.5 Million - $30.5 Million	685,007 Added 115.59%	1,277,625 $52.2 Million
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $10.8 Million - $15.5 Million	349,810 Added 144.07%	592,618 $19.5 Million
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $8.17 Million - $9.9 Million	242,808 New	242,808 $9.87 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.